NCT00026091View on ClinicalTrials.gov

Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

March 31, 2004

Conditions
Recurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IV Ovarian Epithelial CancerStage IV Primary Peritoneal Cavity Cancer
Interventions
DRUG

fenretinide

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

90033-0804

University of Southern California, Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00026091 - Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter